… Inc, Bicara Therapeutics, Fore Biotherapeutics, Leo Pharma, Pyxis, Tubulis, Merck, and Novartis …

… the third strategic brand within LEO Pharma’s global dermatology portfolio.1 … “With our specialization in dermatology, LEO Pharma is uniquely positioned to take … IL-36-mediated dermatoses.5 LEO Pharma will assume responsibility for commercialization …

… Annual Meeting in Paris, France, LEO Pharma presented two late-breaking abstracts … advantages in specificity and safety. LEO Pharma has obtained a worldwide exclusive … , Science, Search & Innovation at LEO Pharma. References 1. Weidinger S, et …

… marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation … 977 (761) N.m. About LEO Pharma LEO Pharma is a global leader in … : BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: LEO Pharma Copyright Business Wire 2025. PUB …

… approval of delgocitinib cream (Anzupgo; LEO Pharma) for the treatment of moderate … and Support for Patients As LEO Pharma moves forward with commercialization, patient … the immediate approval for CHE, LEO Pharma is already exploring additional indications …

… eczema in the U.S., Leo Pharma A/S’s Anzupgo …

… cream from dermatological medicines specialist LEO Pharma. The Wednesday regulatory decision for … a prepared statement. Photo by LEO Pharma

LEO Pharma has gained the US Food … to CHE onset and flares. LEO Pharma CEO Christophe Bourdon said: “Anzupgo … introducing Anzupgo to US patients, LEO Pharma has expanded its operations by …

… U.S. patients, LEO Pharma has significantly upscaled its … Christophe Bourdon, CEO, LEO Pharma.“After successfully launching ANZUPGO in … license agreement in which LEO Pharma gained exclusive rights … with CHE.13 About LEO Pharma LEO Pharma is a global leader …